Where’s the Bottom? Yet Another Tough Week in Bios
Recap - The S&P 500 and the NASDAQ ended the Friday trading session in the green, both nearly flat year-to-date, while the biotech sector continued sliding lower … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
On the Bio Sector: Get Comfortable in the Unknown
Insights - What do you do in a choppy environment? Know what you own, why, and try to get comfortable.
Read nowWhat’s with Legislators and Drugs this Week? Weekly Recap
Recap - First, W.V. Democratic Senator Joe Manchin introduced a bill last week to overturn the FDA’s marketing approval of Zohydro ER, an opioid pain product developed by Zogenix Inc. (ZGNX) and approved just last … Continue Reading
Read now
More Money! Why Tekmira is Worth Revisiting
Research - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read now
Emergent BioSolutions Is Building An Enviable BioDefense Portfolio
Research - Back by government defense contracts, this developer of biodefense drugs and vaccines has real staying power.
Read now
Why Sunshine Heart’s Enrollment Issues Are Concerning
Research - Sunshine Heart's (SSH) fourth quarter call was revealing regarding ongoing enrollment problems. Read on to get our take.
Premium
Alexion Raises Guidance: New Tax Structure, R&D Initiatives to Drive Interest in 2014
Insights - Alexion (ALXN) raised guidance this week with reimbursement news from France. Here's more on the company's 2014.
Read now